Precision BioSciencesDTIL -4.37%50 PB Ratio is 2.90 as of Jul. 11, 2026, which is 22% above its 10-year median of 2.37. GuruFocus rates DTIL with a GF Score™ of 50/100 and a GF Value™ of $1.83 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,227 Biotechnology companies, Precision BioSciences ranks worse than 51.18% on this metric.
The historical rank and industry rank for Precision BioSciences's PB Ratio or its related term are showing as below:
DTIL'
s PB Ratio Range Over the Past 10 Years
Min: 0.54 Med: 2.37 Max: 68.63
Current: 2.9
During the past 9 years, Precision BioSciences's highest PB Ratio was 68.63. The lowest was 0.54. And the median was 2.37.
DTIL's PB Ratio is ranked worse than 51.18% of 1227
companies
in the Biotechnology industry
Industry Median: 2.95
vs DTIL: 2.90
During the past 12 months, Precision BioSciences's average Book Value Per Share Growth Rate was -35.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -38.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -37.30% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Precision BioSciences was 22.50% per year. The lowest was -46.50% per year. And the median was -41.40% per year.
Back to Basics: PB Ratio
Precision BioSciences (NAS:DTIL) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Precision BioSciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precision BioSciences PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Precision BioSciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Precision BioSciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Precision BioSciences (DTIL) has a PB Ratio of 2.90 as of Jul. 11, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Precision BioSciences and its competitors. This is 22% above median its historical median of 2.37. Over the past decade, Precision BioSciences' PB Ratio has ranged from 0.54 to 68.63. According to the industry distribution chart, Precision BioSciences ranks #628 out of 1227 companies in the Biotechnology industry, placing it in the top 51.2%.
Is Precision BioSciences' PB Ratio too high?
Precision BioSciences' current PB Ratio of 2.90 is 22% above median its 10-year median of 2.37. Over the past 10 years, this metric has ranged from a low of 0.54 to a high of 68.63. The Biotechnology industry median PB Ratio is 2.95. Precision BioSciences' value of 2.90 is 1.7% below this industry median. Based on the distribution chart, Precision BioSciences ranks #628 out of 1227 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Precision BioSciences has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Precision BioSciences' PB Ratio compare to NBP and HUMA?
According to the Biotechnology industry distribution chart, Precision BioSciences ranks #628 out of 1227 companies for PB Ratio. This places Precision BioSciences in the lower half of its industry. The industry median PB Ratio is 2.95. Precision BioSciences' value of 2.90 is 1.7% below this benchmark. Historically, Precision BioSciences' own PB Ratio has ranged from 0.54 to 68.63 over the past decade. While the company's 10-year median is 2.37 vs. the industry median of 2.95, Precision BioSciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Precision BioSciences's current PB Ratio of 2.90 is 1.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Precision BioSciences and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Precision BioSciences's current PB Ratio is 2.90, which is 22% above median its own 10-year median of 2.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precision BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Precision BioSciences (DTIL) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.83, compared to a current price of $8.77 — trading 379% above its estimated fair value. The current PB Ratio is 2.90, which is 22% above median its 10-year median of 2.37 and 1.7% below the Biotechnology industry median of 2.95. Precision BioSciences' overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Precision BioSciences (DTIL), the current PB Ratio is 2.90 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Precision BioSciences (DTIL) Overvalued in 2026?
Based on GuruFocus' analysis, Precision BioSciences stock appears to be overvalued.
The current stock price of $8.77 is trading 379% above its estimated GF Value™ of $1.83.
GuruFocus considers Precision BioSciences to be Significantly Overvalued.
Key valuation signals for DTIL:
PB Ratio: 2.90 (22% above median its 10-year median of 2.37)
GF Value™: $1.83 vs. price of $8.77 (379% above fair value)
Industry Position: 1.7% below the Biotechnology median (#628 of 1227)
No single metric tells the full story. See the DTIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
50GF Score
Get the complete analysis for DTIL
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DTIL has been successfully added to your 
